• Andréa Larissa Ribeiro Pires, José Gomes Batista, José Mendes Aldrighi, Irineu Francisco Delfino Silva Massaia, Diego Medeiros Delgado, Edson Santos Ferreira-Filho, and José Maria Soares-Junior.
• . Departamento de Obstetrícia e Ginecologia - Centro de Ciências Médicas - Universidade Federal da Paraíba (UFPB), João Pessoa, PB, Brasil.
• Rev Assoc Med Bras (1992). 2020 Jan 1; 66Suppl 2 (Suppl 2): 22-26.

ObjectivesThe outbreak of coronavirus disease (COVID-19) is a public health emergency of international concern. Inflammatory changes are part of COVID-19 pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. We aimed to discuss the main aspects related to this issue and propose management strategies for women affected by COVID-19.MethodsThis narrative review collected information from several articles published since the beginning of the outbreak of the new coronavirus disease about the pathophysiology, stage of the disease, the occurrence of thrombotic events, and the risk of thromboembolism in users of contraception and hormonal therapy.ResultsThis article consolidates clinical parameters about the risk of venous thromboembolism in users of contraception and menopausal hormone therapy emphasizing the probable increase of that risk in women with suspected or confirmed COVID-19 and bringing safer recommendations.ConclusionsIn this scenario, apart from the fundamental orientations of preventive measures, like social isolation and hygiene, it is important that all female health professionals have knowledge of the new rules and adopt safety measures, especially on the prescription of hormonal therapy and contraception.

13 keywords...

hide…